Post-Pandemic Aftermath: A Two-Year Follow-Up of the Effect of COVID-19 on Oncological Outcomes after Radical Prostatectomy for Prostate Cancer.

COVID lockdown oncological outcomes prostatectomy

Journal

Archivos espanoles de urologia
ISSN: 0004-0614
Titre abrégé: Arch Esp Urol
Pays: Spain
ID NLM: 0064757

Informations de publication

Date de publication:
Jan 2024
Historique:
medline: 20 2 2024
pubmed: 20 2 2024
entrez: 19 2 2024
Statut: ppublish

Résumé

This study aimed to evaluate the indirect effect of the Coronavirus Disease 2019 (COVID-19) pandemic on the surgical outcomes and oncological results of patients who underwent surgery during the lockdown period. We analysed data from 423 patients who underwent radical prostatectomy between 2016 and 2022, with a cut-off date of March 16, 2020. Patients were categorised into two groups, namely, pre-lockdown (n = 289) and during lockdown (n = 134). Perioperative variables, histopathological findings and oncological outcomes, including prostate-specific antigen (PSA) levels and biochemical recurrence (BCR), were assessed. The number of radical prostatectomy increased by 24.26% during lockdown. The study included patients with a mean follow-up of 21 months. A nonsignificant trend towards a higher PSA level at presentation was found (14.22 vs. 12.53 ng/dL, The COVID-19 pandemic led to poor postoperative results. Through a 2-year follow-up, this research investigated the effect of the pandemic on the oncological outcomes, particularly BCR, of patients who underwent radical prostatectomy. Further extended investigations and multi-institutional studies should be conducted to quantify the effect of the pandemic on various cancer outcomes and inform crisis management strategies.

Identifiants

pubmed: 38374012
pii: 1706774234799-204394203
doi: 10.56434/j.arch.esp.urol.20247701.6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

43-48

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Auteurs

Mihnea Bogdan Borz (MB)

Urology Department, The Oncology Institute "Prof. Dr. Ion Chiricuţă", 400015 Cluj-Napoca, Romania.
Iuliu Hatieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.

Vlad Horia Schitcu (VH)

Urology Department, The Oncology Institute "Prof. Dr. Ion Chiricuţă", 400015 Cluj-Napoca, Romania.
Iuliu Hatieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.

Nicolae Crisan (N)

Iuliu Hatieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.
Urology Department, Clinical Municipal Hospital, 400139 Cluj-Napoca, Romania.

Bogdan Petrut (B)

Urology Department, The Oncology Institute "Prof. Dr. Ion Chiricuţă", 400015 Cluj-Napoca, Romania.
Iuliu Hatieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.

Bogdan Adrian Buhas (BA)

Urology Department, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania.

Paul Cristian Borz (PC)

Gastroenterology Department, Regional Institute of Gastroenterology and Hepatology Prof. Dr. Octavian Fodor, 400394 Cluj-Napoca, Romania.

Dan Valean (D)

Iuliu Hatieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.
General Surgery Department, Regional Institute of Gastroenterology and Hepatology Prof. Dr. Octavian Fodor, 400394 Cluj-Napoca, Romania.

Igor Duquesne (I)

Urology department, Cochin Hospital-Port Royal, 75014 Paris, France.

Ioan Coman (I)

Iuliu Hatieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.

Classifications MeSH